期刊文献+

HLA-A^*0201限制性CTL表位肽分子力场分析

Molecular Field Analysis on HLA-A^* 0201 Restricted CTL Epitope
下载PDF
导出
摘要 运用比较相似性指数分析(CoMISA)方法研究了203个HLA-A*0201限制性CTL表位九肽结构与亲和性间的关系,另外30个表位九肽作为预测集用于检验模型的预测能力.得到构效关系模型结果q2=0.548,r2=0.963,F=553.4,SD=0.154.在CoMSIA计算中,当引入疏水场时,三维构效关系模型能得到明显改善.通过该三维构效关系模型,可较精确地估算预测集中30个CTL表位肽与HLA-A*0201间的亲和力(r2pred=0.532,SD=0.454).通过分析分子场等值面图在空间的分布,可以观察到表位肽分子周围的立体及疏水特征对表位肽H与A-A*0201间结合亲和力的影响,从而为进一步对CTL表位肽进行结构改造,并基于此进行治疗性疫苗分子设计提供理论基础. Using comparative molecular similarity indices analysis (CoMSIA), this paper studies relationship between the structure and affinity of a set of 203 restricted CTL peptides, and uses another 30 peptides as predictive set to determine the predictive value of test models, resulted in structure-activity relationship model is q^2 = 0. 548 and r^2 pred = 0.532. When hydrophobic field is introduced into CoMSIA calculation, 3- dimensional structure-activity. Relationship model can be improved considerably. According to the model, the affinity between the 30 CTL peptides in the predictive set and HLA-A^* 0201 can be exactly estimated ( rpred^2 = 0.532, SD = 0.454). By analyzing the spatial distribution of surface chart of isoline, the effect of the 3-D and hydrophobic characteristics of eptode on epitode H and HLA-A^* 0201 can be observed, which provides theoretical basis for further structural transformation of CTL peptides and the molecular design for therapeutic vaccine.
出处 《重庆工学院学报》 2007年第7期1-7,共7页 Journal of Chongqing Institute of Technology
基金 国家自然科学基金资助项目(30471579) 重庆市自然科学基金资助项目(CSTC 2005BB5075)
关键词 细胞毒性T淋巴细胞(CTL) 表位 CoMISA Cytotoxic T Lymphocyte (CTL) epitope peptide CoMISA
  • 相关文献

参考文献12

  • 1Frahm N, Korber B T, Adams C M, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities [J]. J Virol,2(D4,78(5) :2187 - 2200.
  • 2Takedatsu H, Shichijo S, Katagiri K, et al. Identification of peptide vaccine candidates sharing among HLA-A3 +, All+ , -A31 + , and -A33 + cancer pationts[J]. Clin Cancer Res,2004,10(3) : 1112 - 1120.
  • 3Webb A I, Dunstone M A, Chen W, et al. Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue[J]. J Biol Chem, 2004,279(22): 23438- 23446.
  • 4Yamaguchi H, Tanaka F, Ohta M, et al. Identification HLA-APA- restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response[J]. Clin Cancer Res, 2004,10(3) : 890 - 896.
  • 5Hebart H, Rauser G, Stevanovic S, et al. A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneie stem cell transplantation[ J]. Exp Hematol, 2003,31 (10) :966 - 973.
  • 6De Groot A S, Jesdale B, Martin W, et al. Mapping crossclade HIV- 1 vaccine epitopes using a bioinformatics ap- proach[J]. Vaccine, 2003, 21 (27/28/29/30): 4486 - 4504.
  • 7Rongcun Y, Salazar Onfray F, Charo J, et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas[J]. J Immunol, 1999, 163(2) : 1037 - 1044.
  • 8Sette A, Vitiello A, Reherman B, et al. The relationship between class Ⅰ binding affinity and immunogenicity of potential cytotoxic T cell epitopes[J]. J Immunol, 1994,153 (12) : 5586 - 92.
  • 9Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression[J]. J Immunol, 1995, 154(8): 3961 - 3968.
  • 10Tsai V, Southwood S, Sidney J, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptidepulsed dendritic cdls[J]. J Immunol,1997, 158: 1796.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部